Modelling major depression epidemiology and assessing the impact of antidepressants on population health

International Review of Psychiatry

Volumn 17, Issue 3, 2005, Pages 205-211

  Patten, Scott B ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HUMAN; MAJOR DEPRESSION; MATHEMATICAL MODEL; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG MONITORING; HUMANS; MODELS, BIOLOGICAL; PUBLIC HEALTH;

EID: 20444443577     PISSN: 09540261     EISSN: None     Source Type: Journal    
DOI: 10.1080/09540260500072242     Document Type: Review

References (41)

1. Ayuso-Mateos, J. L. (2003). Global burden of unipolar depressive disorders in the year 2000. Global Burden of Disease Draft 28-05-03. World Health Organization Global Program on Evidence for Health Policy (GPE). 1-13.
2. Badamgarav, E., Weingarten, S. R., Henning, J. M., Knight, K., Hasselblad, V., Gano, A., et al. (2003). Effectiveness of disease management programs in depression: a systematic review. American Journal of Psychiatry, 160, 2080-2090.
3. Barendregt, J. J., Van Oortmarssen, G. J., Vos, T., & Murray, C. J. L. (2003). A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Population Health Metrics, 1, 4.
4. Bristow, K., & Patten, S. B. (2002). Treatment-seeking rates and associated mediating factors among individuals with depression. Canadian Journal of Psychiatry, 47, 660-665.
5. Brugha, T. S., Bebbington, P. E., & Jenkins, R. (1999). A difference that matters: comparisons of structured and semi-structured psychiatric diagnostic interviews in the general populations. Psychological Medicine, 29, 1013-1020.
6. Brugha, T. S., Bebbington, P. E., Jenkins, R., Meltzer, H., Taub, N. A., Janas, M., et al. (1999). Cross validation of a general population survey diagnostic interview: a comparison of CIS-R with SCAN ICD-10 diagnostic categories. Psychological Medicine, 29, 1029-1042.
7. Carlsten, A., Waern, M., Ekedahl, A., & Ranstam, J. (2001). Antidepressant medication and suicide in Sweden. Pharmacoepidemiology and Drug Safety, 10, 525-530.
8. Coryell, W., Akiskal, H., Leon, A. C., Winokur, G., Maser, J. D., Mueller, T. I., et al. (1994). The time course of non-chronic major depressive disorder. Archives of General Psychiatry, 51, 405-410.
9. Dumam, R. S. (2002). Synaptic plasticity and mood disorders. Molecular Psychiatry, 7, s29-s34.
10. Fava, G. A. (2003). Can long-term treatment with antidepressant drugs worsen the clinical course of depression? Journal of Clinical Psychiatry, 64, 123-133.
11. Goldman, L., Coxson, P., Hunink, M. G. M., Goldman, P. A., Tosteson, A. N. A., Mittleman, M. A., et al. (1999). The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II Guidelines. Journal of the American College of Cardiology, 34, 768-776.
12. Goldman, L., Weinstein, M. C., & Williams, L. W. (1989). Relative impact of targeted versus population-wide cholesterol interventions on the incidence of coronary heart disease. Projections of the Coronary Heart Disease Policy Model. Circulation, 80, 254-260.
13. Hemels, M. E. H., Koren, G., & Einarson, T. R. (2002). Increased use of antidepressants in Canada: 1981-2000. Annals of Pharmacotherapy, 36, 1375-1379.
14. Hollenberg, J. P. (1984). Markov cycle trees: a new representation for complex Markov processes. Medical Decision Making, 4, 529.
15. Isacsson, G. (2000). Suicide prevention - A medical break-through? Acta Psychiatrica Scandinavica, 102, 113-117.
16. Katon, W., Von Korff, M., Lin, E., Unutzer, J., Simon, G., Walker, E., et al. (1997). Population-based care of depression: effective disease management strategies to decrease prevalence. General Hospital Psychiatry, 19, 169-178.
17. Keller, M. B., & Hanks, D. L. (1994). The natural history and heterogeneity of depressive disorders: Implications for rational antidepressant therapy. Journal of Clinical Psychiatry, 55(Suppl. A), 25-31.
18. Keller, M. B., Lavori, P. W., Mueller, T. I., Endicott, J., Coryell, W., Hirschfeld, R. M. A., et al. (1992). Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Archives of General Psychiatry, 49, 809-816.
19. Kessler, R. C., Andrews, G., Colpe, L. J., Hiripi E., Mroczek, D. K., & Normand, S. L. (2002). Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychological Medicine, 32, 959-976.
20. Last, J. M. (1995). A dictionary of epidemiology (Third Edition). Oxford: Oxford University Press.
21. McManus, P., Mant, A., Mitchell, P. B., Montgomery, W. S., Marley, J., & Auland, M. E. (2000). Recent trends in the use of antidepressant drugs in Australia, 1990-1998. Medical Journal of Australia, 173, 461.
22. Middleton, N., Gunnell, D., Whitely, E., Dorling, D., & Frankel, S. (2001). Secular trends in antidepressant prescribing in the UK, 1975-1998. Journal of Public Health Medicine, 23, 262-267.
23. Murray, C. J. L., & Lopez, A. C. (1996). Global burden of disease and injury. Boston: Harvard School of Public Health.
24. Nuijten, M. J. C. (2001). Assessment of clinical guidelines for continuation treatment in major depression. Value in Health, 4, 281-294.
25. Patten, S. B. (2002a). A framework for simulating the impact of antidepressant medications on population health status. Pharmacoepidemiology and Drug Safety, 11, 549-559.
26. Patten, S. B. (2002b). Progress against major depression in Canada. Canadian Journal of Psychiatry, 47, 775-780.
27. Patten, S. B. & Beck, C. A. (2004a). Major depression and mental health care utilization in Canada, 1994-2000. Canadian Journal of Psychiatry, 49, 303-309.
28. Patten, S. B. & Beck, C. A. (2004b). Major depression and mental health care utilization in Canada: 1994-2000. Canadian Journal of Psychiatry, 49, 303-309.
29. Patten, S. B. & Lee, R. C. (2004a). Refining estimates of major depression incidence and episode duration in Canada using aMonte Carlo Markov model. Medical Decision Making, 4, 351-358.
30. Patten, S. B., & Lee, R. C. (2004b). Towards a dynamic description of major depression epidemiology. Epidemiologia e Psichiatria Sociale, 13, 21-28.
31. Regier, D. A., Kaelber, C. T., Rae, D. S., Farmer, M. E., Knauper, B., Kessler, R. C., et al. (1998). Limitations of diagnostic criteria and assessment instruments for mental disorders. Archives of General Psychiatry, 55, 09-115.
32. Roberts, E., & Norris, P. (2001). Growth and change in the prescribing of anti-depressants in New Zealand: 1993-1997. New Zealand Medical Journal, 114, 25-27.
33. Rothman, K. J., & Greenland, S. (1998). Measures of disease frequency. In K. J. Rothman, & S. Greenland (Eds), Modern Epidemiology (pp. 29-64, Second Edition). Philadelphia: Lippincott-Raven.
34. Sheehan, D. V., Lecrubier, Y., Sheehan, H., Amorim, P., Janavs, J., Weiller, E., et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59 (Suppl 20), 22-33.
35. Silverstein, M. D., Albert, D. A., Hadler, N. M., & Ropes, M. W. (1988). Prognosis in SLE: comparison of Markov model to life table analysis. Journal of Clinical Epidemioogy, 41, 623-633.
36. Sonnenberg, F. A., & Beck, J. R. (1993). Markov models in medical decision-making: a practical guide. Medical Decision Making, 13, 322-338.
37. Sorensen, J., & Kind, P. (1995). Modelling cost-effectiveness issues in the treatment of clinical depression. IMA Journal of Mathematics Applied in Medicine and Biology, 12, 369-385.
38. Spanier, C., Frank, E., Mceachran, A. B., Grochocinski, V. J., & Kupfer, D. J. (1996). The prophylaxis of depressive episodes in recurrent depression following discontinuation of drug therapy: integrating psychological and biological factors. Psychological Medicine, 26, 461-475.
39. Valenstein, M., Vijan, S., Zeber, J. E., Boehm, K., & Buttar, A. (2001). The cost-utility of screening for depression in primary care. Annals of Internal Medicine, 134, 418-420.
40. Von Korff, M., & Parker, R. D. (1980). The dynamics of the prevalence of chronic episodic disease. Journal of Chronic Disease, 33, 79-85.
41. Weinstein, M. C., Coxson, P. G., Williams, L. W., Pass, T. M., Stason, W. B., & Goldman, L. (1987). Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. American Journal of Public Health, 77, 1417-1426.